�Anadis Limited (ASX: ANX), a research driven biopharmaceutical company focussed on polyclonal antibodies to address human disease, announced important advancement concerning its accelerated programme to develop a nasal antibody spray to provide immediate post-exposure prophylaxis against a compass of grippe viruses.
Working with an animal influenza challenge theoretical account in the laboratory of Professor Loreena Brown at the Department of Microbiology and Immunology, University of Melbourne, scientists successfully completed a series of proof-in-principal experiments. These experiments victimization an brute model intentional specifically to test flu prevention and treatment, demonstrated the power of Anadis' all born antibody nasal spray conceptualisation to "cut" virus replication at the respiratory tract lining. The studies indicated a substantial impact of single and daily dose of the Anadis polyclonal antibodies in reducing the likelihood of infection and reducing the severity of those septic with flu.
Scientists from the University of Melbourne and Anadis teams are in the process of submitting data for publishing and intend to portray the details at an upcoming grippe control group discussion.
Anadis CEO Dr. Zeil Rosenberg stated, "Our newfangled topical spray approach to protecting individuals during seasonal worker or epidemic flu outbreaks is a radical new paradigm to protect people from these influenza viruses. The fact that the Anadis antibodies are all natural and topically applied means we may have a very safe and effective newfangled approach to provide immediate protection to all persons and be able to address multiple virus strains. We know from electric current failures in vaccine protection among many persons this past year that indeed novel approaches like this are urgently needed."
Anadis VP for Business Development Oren Fuerst further noted, "This work supports an aggressive commercial strategy expanding our intellectual property position in this unique field. Our feeler shows for the showtime time a cost effective method of fighting influenza using antibodies. We plan to displace on our own and with partners to wreak this revolutionary product to market."
Anadis' polyclonal antibodies are obtained using its own proprietorship approach to vaccinating dairy farm cows and then leverage advanced dairy farm industry methods collect first-milking colostrum under GMP conditions, where it is further formulated as a spray dried powder, for later reconstitution as an all natural os nasale spray.
Anadis
More info
